KLOR-CON M10
Clinical safety rating: caution
Comprehensive clinical and safety monograph for KLOR-CON M10 (KLOR-CON M10).
Potassium chloride dissociates to release potassium ions which are essential for maintaining cellular membrane potential, nerve impulse transmission, muscle contraction, and acid-base balance. Replacement of potassium deficits prevents or corrects hypokalemia.
| Metabolism | Potassium chloride is not metabolized; it is excreted primarily by the kidneys, with minor losses via feces and sweat. Renal handling involves glomerular filtration, tubular reabsorption, and secretion. |
| Excretion | Renal: >90% of potassium intake is excreted by the kidneys, primarily via distal tubular secretion. |
| Half-life | Not applicable; potassium is an electrolyte with continuous homeostatic regulation. The plasma half-life of potassium is approximately 2-3 hours, but this is not clinically meaningful as elimination is dependent on renal function and total body stores. |
| Protein binding | Minimal (<5%); potassium is primarily free in plasma. |
| Volume of Distribution | Approximately 0.5 L/kg (total body water); distribution is primarily intracellular (98% of total body potassium is intracellular). |
| Bioavailability | Oral: >90% for potassium chloride solutions; extended-release tablets have approximately 60-80% bioavailability due to incomplete release. |
| Onset of Action | Oral (immediate-release): 30-60 minutes. Extended-release (such as Klor-Con M10): 2-4 hours. |
| Duration of Action | Oral (immediate-release): 4-6 hours. Extended-release: 8-12 hours. Duration depends on renal function and potassium balance. |
For potassium depletion: 10 mEq orally three to four times daily, with maximum single dose of 20 mEq and total daily dose up to 100 mEq. Dosage must be individualized based on serum potassium levels and clinical response.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | For GFR 30-59 mL/min: reduce dose by 25-50% and monitor potassium closely. For GFR 15-29 mL/min: reduce dose by 50-75% and monitor potassium frequently. For GFR <15 mL/min: avoid use unless severe deficiency and monitoring is meticulous. Contraindicated in oliguria or rapidly deteriorating renal function. |
| Liver impairment | No dose adjustment specifically required for hepatic impairment per Child-Pugh classification; however, patients with hepatic cirrhosis may have increased sensitivity to potassium and require close monitoring to avoid hyperkalemia. |
| Pediatric use | Dose based on serum potassium deficit: 1-3 mEq/kg/day divided every 6-8 hours orally, not to exceed 1 mEq/kg per single dose or 10 mEq per dose. Maximum daily dose: 3 mEq/kg/day. Monitor serum potassium frequently. |
| Geriatric use | Start at lower end of adult dosing (10 mEq one to two times daily) due to age-related decline in renal function and increased risk of hyperkalemia. Monitor renal function and serum potassium levels frequently. Avoid use if creatinine clearance <30 mL/min unless severe deficiency and close monitoring. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for KLOR-CON M10 (KLOR-CON M10).
| Breastfeeding | Potassium is a normal component of breast milk. Exogenous potassium from supplements is unlikely to affect the infant, as the body maintains potassium homeostasis. No specific M/P ratio is available; however, levels in milk are not expected to be clinically significant. |
| Teratogenic Risk | Potassium chloride is generally considered low risk in pregnancy. No teratogenic effects have been reported. However, because hypokalemia itself can cause adverse pregnancy outcomes (e.g., cardiac arrhythmias), maintaining normal potassium levels is important. There are no well-controlled studies in pregnant women; use only if clearly needed. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hyperkalemia (serum potassium > 5.5 mEq/L or any elevation above normal)","Concurrent use of potassium-sparing diuretics or ACE inhibitors that may increase risk of hyperkalemia","Severe renal impairment with oliguria, anuria, or azotemia","Untreated Addison's disease","Adynamic ileus, mechanical obstruction, or severe gastrointestinal narrowing","Solid oral forms are contraindicated in patients with esophageal compression or delayed gastric emptying"]
| Precautions | ["Cardiac arrest and fatal hyperkalemia can occur if potassium is given too rapidly or in excessive amounts, especially in patients with impaired renal function.","Use with caution in patients with cardiac disease, renal insufficiency, or conditions that predispose to hyperkalemia (e.g., acidosis, adrenal insufficiency).","Solid oral dosage forms (tablets/capsules) may cause gastrointestinal lesions; use with caution in patients with gastrointestinal obstruction, stricture, or delayed gastric emptying.","Serum potassium levels should be monitored frequently during therapy."] |
Loading safety data…
| Fetal Monitoring | Monitor serum potassium levels periodically, especially during prolonged therapy or when combined with other medications affecting potassium. Consider maternal ECG if potassium levels are abnormal. No specific fetal monitoring required unless maternal electrolyte imbalance occurs. |
| Fertility Effects | No known effects on fertility from potassium chloride. However, underlying conditions requiring potassium supplementation (e.g., renal disease) may impact fertility. |